Participant Recruitment and Screening Coordination in Peptide Trials

Question: In a peptide clinical trial, which recruitment and screening tasks are regulated, which are logistical, and what should a study team measure to keep enrollment both efficient and compliant?

Type: Sourced desk research.

Method

This review reads the primary rules that govern investigational drug studies and human-subject protections, plus the official registry and FDA guidance pages that describe how trials are registered and conducted. The evidence base is:

• 21 CFR Part 312, which governs investigational new drug applications.
• 45 CFR Part 46, which describes the protections for human subjects, including informed consent and institutional review board review.
• The ClinicalTrials.gov registry, which is the public record of registered studies.
• The FDA guidance document library, which is the authoritative index of the agency's current thinking.
• The FDA drug information resources, used to confirm the regulatory context.
• 21 CFR Part 11, which addresses electronic records and electronic signatures.

The method is qualitative. I separate the regulatory gate (what must be true before a person may participate) from the logistical task (how the person is found, scheduled, and tracked). Statements drawn from the sources are labeled source facts; process recommendations are labeled interpretation. This is a synthesis of the rules, not legal advice, and it does not address the scientific merits of any product or protocol.

What the sources say

Investigational drug studies operate under an IND framework. 21 CFR Part 312 describes the requirements for investigational new drug applications, including the conditions under which an investigational drug may be shipped and administered. (Source facts.) The framework places responsibility on the sponsor and the investigator, and it assumes that participants are enrolled under an approved protocol. (Interpretation.)

Human-subject protections define consent and review. 45 CFR Part 46 describes the protections for human subjects, including the requirement for informed consent and for institutional review board review of research. (Source facts.) Consent is a process with documentation, not a signature collected for convenience. (Interpretation.)

The registry is a public record. ClinicalTrials.gov is the registry and results database where applicable studies are registered. (Source fact.) Because the registry is public, recruitment claims that a study team makes externally should be consistent with what the registry says. (Interpretation.)

FDA guidance is the current-thinking index. The FDA guidance document library indexes the agency's guidance documents, including those on clinical trial conduct. (Source fact.) Where a study uses a novel peptide or a complex endpoint, checking the current guidance index is part of protocol planning. (Interpretation.)

Electronic records may be in scope. 21 CFR Part 11 addresses electronic records and electronic signatures in FDA-regulated records. (Source fact.) Screening logs, eligibility records, and consent documentation kept electronically can fall within this scope, so the system that holds them matters. (Interpretation.)

The drug context is regulated end to end. The FDA drug information resources describe the approval and oversight context for drug products. (Source fact.) A peptide study is not a standalone marketing exercise; it sits inside a regulated development path. (Interpretation.)

Registration creates a public trail. The registry describes itself as the public record of studies, which means the study's own recruitment and eligibility statements should be consistent with what is registered. (Source fact.) A coordination team that prepares screening scripts, call guides, and recruitment materials should therefore work from the registered record, and should route any change in eligibility criteria or study status through the appropriate amendment and update process. (Interpretation.) The practical control is straightforward: no external recruitment copy goes out without a check against the current registered description.

Findings

1. Recruitment and screening are different processes with different risks. Recruitment brings potential participants into contact with the study; screening determines whether they are eligible. Mixing them in one queue hides the point at which errors occur. (Interpretation built on 21 CFR Part 312 and 45 CFR Part 46.)
2. Consent precedes procedures, and eligibility is documented. Under 45 CFR Part 46, informed consent and review are structural requirements, and under 21 CFR Part 312, investigational drug use follows the protocol. The practical consequence is that a screening activity that goes beyond what is permitted before consent is a compliance problem, not just a workflow choice. (Synthesis of the sources.)
3. Screen-fail data is high-value and usually underused. Capturing the reason a candidate does not proceed turns screening into a feedback loop for protocol design and referral targeting. (Interpretation.)
4. Public registration constrains external messaging. Because the registry is public, recruitment materials that overstate eligibility or benefits create a consistency problem as well as an ethical one. (Synthesis of the registry source.)
5. The record system is part of the control. Attribution, audit trails, and signature handling are the same issues that appear in other regulated records, and electronic systems bring them into scope. (Synthesis of 21 CFR Part 11.)
6. The funnel has more stages than an enrollment count suggests. Referral, first contact, prescreen, consent, formal screening, and enrollment are distinct stages, and each can lose candidates for different reasons. Measuring conversion stage by stage shows whether the constraint is reachability, eligibility, scheduling, or willingness to consent. (Interpretation.)
7. Training and delegation are part of the control. Support staff can coordinate logistics and records, but eligibility determinations and consent discussions should be handled by personnel qualified for those tasks under the protocol and applicable rules. Defining that boundary in writing protects both the participant and the study. (Synthesis of 45 CFR Part 46 and 21 CFR Part 312.)

Operational implications

Translating the sources into checkpoints for a peptide study team, with qualified regulatory and legal advisors confirming the specifics:

• Keep the recruitment register and the screening log separate. Record source of referral, first contact date, and disposition for each.
• Document eligibility against the protocol, item by item. Do not summarize eligibility in a single free-text line.
• Keep consent on its own timeline. Confirm that each pre-consent activity is permitted before consent is obtained.
• Capture screen-fail reasons in a controlled vocabulary. This makes protocol feasibility visible.
• Measure time in screening. The interval from first contact to eligibility decision is a direct measure of coordination load.
• Confirm the record system. If screening or consent records are electronic and in scope, confirm how attribution and signatures work.
• Keep external materials consistent with the registry. Review recruitment copy against the registered record before publication.
• Define who may answer eligibility questions. Qualified study personnel should own eligibility determinations, while support staff coordinate logistics and records.

A proposed minimum measurement set, offered as a starting point rather than a standard: referrals per month by source; screen-fail rate by reason; median days from first contact to eligibility decision; percentage of eligibility records complete at the decision point; and percentage of consent records with complete attribution.

Limitations

This review reads regulation text, a registry description, and a guidance index, not institutional review board determinations, sponsor standard operating procedures, or enforcement actions. It does not determine which studies must register or which rules apply to a specific protocol, and it is not legal advice. It does not address good clinical practice requirements in detail, the specifics of any particular therapeutic area, or the scientific validity of any endpoint. Requirements can differ for device studies, biologics, and studies conducted outside the United States, none of which are examined here. Readers should confirm applicability with qualified regulatory counsel and their institutional review board before relying on this synthesis.

Sources

• 21 CFR Part 312, Investigational New Drug Application (checked September 18, 2026): https://www.ecfr.gov/current/title-21/part/312
• 45 CFR Part 46, Protection of Human Subjects (checked September 18, 2026): https://www.ecfr.gov/current/title-45/part/46
• ClinicalTrials.gov, registry and results database (checked September 18, 2026): https://clinicaltrials.gov/
• U.S. Food and Drug Administration, Guidance Documents (checked September 18, 2026): https://www.fda.gov/regulatory-information/search-fda-guidance-documents
• U.S. Food and Drug Administration, Drugs (context confirmation, checked September 18, 2026): https://www.fda.gov/drugs
• 21 CFR Part 11, Electronic Records; Electronic Signatures (checked September 18, 2026): https://www.ecfr.gov/current/title-21/part/11